Endonovo Therapeutics (ENDV) Debt to Equity (2016 - 2023)
Endonovo Therapeutics has reported Debt to Equity over the past 11 years, most recently at -$0.26 for Q3 2023.
- Quarterly results put Debt to Equity at -$0.26 for Q3 2023, up 3.73% from a year ago — trailing twelve months through Sep 2023 was -$0.26 (up 3.73% YoY), and the annual figure for FY2022 was -$0.54, down 147.19%.
- Debt to Equity for Q3 2023 was -$0.26 at Endonovo Therapeutics, up from -$0.26 in the prior quarter.
- Over the last five years, Debt to Equity for ENDV hit a ceiling of -$0.22 in Q4 2021 and a floor of -$0.54 in Q4 2022.
- Median Debt to Equity over the past 5 years was -$0.3 (2020), compared with a mean of -$0.34.
- Biggest five-year swings in Debt to Equity: skyrocketed 43.44% in 2020 and later crashed 147.19% in 2022.
- Endonovo Therapeutics' Debt to Equity stood at -$0.52 in 2019, then skyrocketed by 43.44% to -$0.29 in 2020, then grew by 25.36% to -$0.22 in 2021, then crashed by 147.19% to -$0.54 in 2022, then soared by 52.34% to -$0.26 in 2023.
- The last three reported values for Debt to Equity were -$0.26 (Q3 2023), -$0.26 (Q2 2023), and -$0.38 (Q1 2023) per Business Quant data.